precisionmedicineonline2h
Regenxbio Treats First Patient in Pivotal Stage of Duchenne Muscular Dystrophy Gene Therapy Trial
The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.
BioSpace4h
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
GMA Network12h
Vaccine shows early promise against aggressive breast cancer
A small trial of an experimental vaccine has shown promising results for patients with the most aggressive type of breast ...
Pharmaceutical Technology17h
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy
RegenxBio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...
Reuters17h
Health Rounds: Vaccine shows early promise against aggressive breast cancer
In mice with muscular dystrophy, the treatment restored large therapeutic muscle proteins to normal levels, the researchers ...
FierceBiotech23h
After seeing improved muscle function in phase 1/2 trial, Regenxbio launches pivotal DMD study
Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...